These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 22607767

  • 1. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study.
    Campagnoli C, Pasanisi P, Abbà C, Ambroggio S, Biglia N, Brucato T, Colombero R, Danese S, Donadio M, Venturelli E, Zito G, Berrino F.
    Clin Breast Cancer; 2012 Jun; 12(3):175-82. PubMed ID: 22607767
    [Abstract] [Full Text] [Related]

  • 2. Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer.
    Campagnoli C, Berrino F, Venturelli E, Abbà C, Biglia N, Brucato T, Cogliati P, Danese S, Donadio M, Zito G, Pasanisi P.
    Clin Breast Cancer; 2013 Dec; 13(6):433-8. PubMed ID: 24267731
    [Abstract] [Full Text] [Related]

  • 3. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet.
    Glueck CJ, Goldenberg N, Sieve L, Wang P.
    Metabolism; 2008 Jul; 57(7):954-60. PubMed ID: 18555837
    [Abstract] [Full Text] [Related]

  • 4. Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study.
    Trolle B, Lauszus FF, Frystyk J, Flyvbjerg A.
    Fertil Steril; 2010 Nov; 94(6):2234-8. PubMed ID: 20189560
    [Abstract] [Full Text] [Related]

  • 5. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
    Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A.
    J Clin Oncol; 2012 Jul 20; 30(21):2593-600. PubMed ID: 22564993
    [Abstract] [Full Text] [Related]

  • 6. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
    Yilmaz M, Bukan N, Ayvaz G, Karakoç A, Törüner F, Cakir N, Arslan M.
    Hum Reprod; 2005 Dec 20; 20(12):3333-40. PubMed ID: 16123091
    [Abstract] [Full Text] [Related]

  • 7. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
    Kriplani A, Agarwal N.
    J Reprod Med; 2004 May 20; 49(5):361-7. PubMed ID: 15214709
    [Abstract] [Full Text] [Related]

  • 8. Insulin-lowering effects of metformin in women with early breast cancer.
    Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG.
    Clin Breast Cancer; 2008 Dec 20; 8(6):501-5. PubMed ID: 19073504
    [Abstract] [Full Text] [Related]

  • 9. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
    Kebapcilar L, Taner CE, Kebapcilar AG, Alacacioglu A, Sari I.
    Arch Gynecol Obstet; 2010 Jan 20; 281(1):35-42. PubMed ID: 19330342
    [Abstract] [Full Text] [Related]

  • 10. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
    Mitkov M, Pehlivanov B, Terzieva D.
    Eur J Obstet Gynecol Reprod Biol; 2006 May 01; 126(1):93-8. PubMed ID: 16360262
    [Abstract] [Full Text] [Related]

  • 11. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
    Kilicdag EB, Bagis T, Zeyneloglu HB, Tarim E, Aslan E, Haydardedeoglu B, Erkanli S.
    Hum Reprod; 2005 Apr 01; 20(4):894-9. PubMed ID: 15618250
    [Abstract] [Full Text] [Related]

  • 12. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
    Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE.
    Fertil Steril; 2004 Oct 01; 82(4):893-902. PubMed ID: 15482765
    [Abstract] [Full Text] [Related]

  • 13. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N.
    Exp Clin Endocrinol Diabetes; 2011 Feb 01; 119(2):63-8. PubMed ID: 21031343
    [Abstract] [Full Text] [Related]

  • 14. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E, Alexandraki K, Piperi C, Aessopos A, Paterakis T, Katsikis I, Panidis D.
    Metabolism; 2007 Jan 01; 56(1):129-34. PubMed ID: 17161235
    [Abstract] [Full Text] [Related]

  • 15. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
    Mitkov M, Pehlivanov B, Terzieva D.
    Eur J Obstet Gynecol Reprod Biol; 2005 Feb 01; 118(2):209-13. PubMed ID: 15653205
    [Abstract] [Full Text] [Related]

  • 16. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
    Hahn S, Quadbeck B, Elsenbruch S, Gärtner R, Finke R, Mann K, Janssen OE.
    Dtsch Med Wochenschr; 2004 May 07; 129(19):1059-64. PubMed ID: 15136950
    [Abstract] [Full Text] [Related]

  • 17. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA, Shin SY, Yoon BK, Choi D.
    Gynecol Endocrinol; 2007 May 07; 23(8):461-7. PubMed ID: 17852414
    [Abstract] [Full Text] [Related]

  • 18. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
    Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo R.
    Clin Pharmacol Ther; 2006 Aug 07; 80(2):105-14. PubMed ID: 16890572
    [Abstract] [Full Text] [Related]

  • 19. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Sahin Y, Unluhizarci K, Yilmazsoy A, Yikilmaz A, Aygen E, Kelestimur F.
    Clin Endocrinol (Oxf); 2007 Dec 07; 67(6):904-8. PubMed ID: 17666089
    [Abstract] [Full Text] [Related]

  • 20. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
    Yilmaz M, Karakoç A, Törüner FB, Cakir N, Tiras B, Ayvaz G, Arslan M.
    Gynecol Endocrinol; 2005 Sep 07; 21(3):154-60. PubMed ID: 16335907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.